Filter Categories
All
White Paper
Blog Post
-
As ADCs continue to get incorporated in the treatment landscape across several solid tumors, data emerging from the next...
-
Chinese pharmaceutical companies present both an opportunity and a threat to their international counterparts. In this blog, we explore...
-
The Chinese regulatory landscape is very different compared to that of the rest of the world. Can businesses bridge...
-
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they...
-
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they...
-
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they...
-
Prescient looks at the critical data presented at the American Society of Hematology (ASH) Annual Meeting and how they...
-
Nature has accepted and published a manuscript from Prescient’s Aakriti Verma in their “Scientific Reports”. This research revealed novel...
-
Last year, Prescient embarked upon the ambitious exercise of interviewing competitive intelligence (CI) practitioners across the pharmaceutical industry to...
-
How you spend your CI budget is as important as how much you are spending; therefore, it is vital...
-
Competitive intelligence (CI) is fundamental to ensuring the success of pharmaceutical companies, whether they are planning a new drug...
-
In this white paper, Ben Doran and Jeanne Penn draw on their experiences in the pharmaceutical field to explain...
-
Virtual workshops have different planning requirements compared to similar events that might take place face to face. Prescient has...
-
Now more than ever, we are facing the question of why we need digital media monitoring (DMM). Competitors are...
-
The impact of COVID-19 on clinical and regulatory affairs, manufacturing and supply chains, and stakeholder engagements has slowed the...
-
Regulatory agencies across the world are issuing flexible guidelines to cater to the COVID-19 public health emergency. This is...
-
Content and offerings are evolving – so should your approach to maximize insights.
-
Do you feel that without a physical congress, you are losing an essential tool in understanding the dynamics of...
-
The continued rise of COVID-19 is expected to have short- and long-term impacts across the key biopharmaceutical functions, and...
-
Prescient has conducted research among competitive intelligence (CI) stakeholders throughout the biopharmaceutical industry to identify the top challenges in...
-
In this white paper, Prescient has identified three industry trends that are shaping competitive dynamics in the US market...
-
Tumor mutational burden (TMB (the number of mutations per megabase of DNA (mut/Mb)) can be a predictor of response...
-
Skin diseases constitute one of the leading causes of health burden worldwide, measured as disability-adjusted life years (DALYs). Among...
-
Activating mutations in the EGFR gene are found in about 10-12% of all non-small cell lung cancer (NSCLC) cases...
-
Lung cancer is the leading cause of cancer mortality worldwide, accounting for more than 1.6 million deaths annually. Non-small...
-
Breast cancer is the most common cancer in women with more than 2.1 million new cases diagnosed in 2018....
-
With regulatory approval, CAR-T cell therapy must address significant unmet needs in clinical practice without restrictions in order to...
-
A largely glossed-over finding from active-controlled trials of checkpoint inhibitors in solid tumors is the delayed crossover of Kaplan-Meier...
-
Access to cancer therapies is a part of every country’s health policy agenda; it, however, is not guaranteed to...
-
By: Tanya Casimiro, PhDAs the first Phase III data in non-alcoholic steatohepatitis (NASH) begin to be released, the next...
-
There is significant interest in companion diagnostics (CDx) throughout the healthcare industry, but for this personalized medicine approach to...
-
Approximately 7,000 rare diseases affect more than 300 million people worldwide, or around 5-8% of the population, depending on...
-
On April 16, 2018, data from multiple pivotal trials in first-line (1L) non-small-cell lung cancer (NSCLC) were presented at...
-
The US healthcare system has been facing great uncertainty, with ongoing challenges to the sustainability of the Affordable Care...